Last reviewed · How we verify
Radioiodine therapy
Radioiodine therapy is a Small molecule drug developed by Fabricio Lopes da Fonseca. It is currently in Phase 1 development.
Radioiodine therapy is used to treat various stages of thyroid gland carcinomas, including metastatic, poorly differentiated, recurrent, stage IV follicular, and stage IV papillary carcinomas. The therapy involves the use of Iodine I-131, a radioactive isotope of iodine with a half-life of about eight days, which targets and destroys cancer cells.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Radioiodine therapy |
|---|---|
| Sponsor | Fabricio Lopes da Fonseca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (PHASE2)
- Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma (PHASE1)
- Adjuvant Radiotherapy in High Risk Locally Advanced DTC (PHASE3)
- The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer (PHASE2)
- A Brief Video Intervention to Improve Patient Outcomes Following Radioiodine Treatment (NA)
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
- CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer
- Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radioiodine therapy CI brief — competitive landscape report
- Radioiodine therapy updates RSS · CI watch RSS
- Fabricio Lopes da Fonseca portfolio CI
Frequently asked questions about Radioiodine therapy
What is Radioiodine therapy?
Who makes Radioiodine therapy?
What development phase is Radioiodine therapy in?
Related
- Manufacturer: Fabricio Lopes da Fonseca — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing